CJC-1295 (No DAC) vs SLU-PP-332: Mechanism, Half-Life & Research Use

Direct Comparison Overview: CJC-1295 (No DAC) vs SLU-PP-332

CJC-1295 (No DAC) is a synthetic growth-hormone-releasing hormone (GHRH) analog that stimulates anterior pituitary somatotrophs to elevate pulsatile GH and downstream IGF-1 levels. Conversely, SLU-PP-332 is a synthetic estrogen-related receptor (ERR) agonist that functions as an exercise mimetic, activating mitochondrial biogenesis and oxidative phosphorylation without altering the somatotropic axis.

While both compounds are investigated in preclinical models of metabolic optimization and physical performance preservation, their biological cascades operate through completely distinct pathways. CJC-1295 (No DAC) relies on cell-surface receptor activation to trigger peptide hormone signaling, whereas SLU-PP-332 directly modulates nuclear transcription factors to alter cellular bioenergetics at the genomic level.

Comparative Specifications and Criteria Matrix

To assist laboratory researchers in selecting the optimal research compound for specific experimental designs, the primary physical and mechanistic properties of CJC-1295 (No DAC) and SLU-PP-332 are summarized below.

| Criterion | CJC-1295 (No DAC) | SLU-PP-332 | | :--- | :--- | :--- | | **Primary Target** | GHRH Receptor (GHRH-R) | Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) | | **Mechanistic Class** | Synthetic GHRH Analog / Secretagogue | Pan-ERR Nuclear Receptor Agonist | | **Biological Half-Life** | ~30 minutes (in vivo rodent) | ~4 to 6 hours (in vivo rodent) | | **Primary Downstream Axis** | Pulsatile GH release -> Hepatic IGF-1 | PGC-1α -> Mitochondrial biogenesis & FAO | | **Solubility Medium** | Sterile Water / Bacteriostatic Water | DMSO / Ethanol / Polyethylene Glycol | | **Primary Preclinical Focus** | Tissue repair, protein synthesis, body composition | Oxidative capacity, endurance, lipid oxidation | | **Standard Experimental Model** | Murine somatotroph assays, wound healing models | Murine metabolic chambers, treadmill endurance assays |

CJC-1295 (No DAC) Mechanistic Profile & Somatotropic Signal Pathways

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a 29-amino-acid peptide derived from human growth-hormone-releasing hormone. The sequence contains four specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) that enhance resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). By binding selectively to the GHRH receptor on anterior pituitary somatotrophs, CJC-1295 (No DAC) activates adenylate cyclase, elevating intracellular cAMP levels and triggering calcium-dependent exocytosis of growth hormone.

In preclinical models, this targeted receptor agonism generates physiological, pulsatile surges of systemic growth hormone. Grounding studies show that CJC-1295 (No DAC) functions as a long-acting growth-hormone-releasing hormone analog that sustains growth hormone and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research. Researchers studying protein translation, collagen synthesis, and cell proliferation frequently utilize CJC-1295 (No DAC) to evaluate somatotropic axis stimulation without causing persistent receptor desensitization.

SLU-PP-332 Mechanistic Profile & ERR Nuclear Receptor Activation

SLU-PP-332 represents an entirely different pharmacological class: small-molecule nuclear receptor agonists. It targets the Estrogen-Related Receptor family, specifically ERRα, ERRβ, and ERRγ. These orphan nuclear receptors serve as master regulators of cellular energy metabolism, controlling transcription programs associated with mitochondrial biogenesis, oxidative phosphorylation, and fatty acid transport.

In vitro data indicate that SLU-PP-332 potently recruits nuclear receptor coactivators such as PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). In rodent models, administration of SLU-PP-332 upregulates gene networks responsible for electron transport chain assembly and beta-oxidation in skeletal muscle, effectively mimicking the cellular signaling cascade induced by acute exercise without requiring physiological activity or endocrine axis manipulation.

Pharmacokinetics, Half-Life, and Chemical Stability

Understanding the kinetic profiles of these research compounds is essential for designing valid dosing regimes in animal models. CJC-1295 (No DAC) exhibits an in vivo half-life of approximately 30 minutes in rodent models. This rapid clearance allows investigators to mimic physiological pulsatile GH release, making it ideal for studies where transient, naturalistic hormone spikes are required rather than continuous elevation.

Conversely, SLU-PP-332 exhibits a extended metabolic stability profile characteristic of synthetic small molecules. With an estimated half-life of 4 to 6 hours in murine plasma, SLU-PP-332 sustains steady nuclear receptor engagement across multi-hour experimental windows. This extended half-life allows researchers conducting metabolic chamber or endurance assays to evaluate chronic oxidative adaptation without requiring continuous micro-infusions.

Preclinical Literature Review: Somatotropic Axis vs. Exercise Mimetic Signaling

Preclinical studies evaluating CJC-1295 (No DAC) center predominantly on its ability to stimulate the somatotropic axis and accelerate cell turnover. Laboratory literature demonstrates that sustained elevations of IGF-1 mediated by GHRH analogs facilitate satellite cell activation, extracellular matrix remodeling, and nitrogen retention in catabolic muscle models. These findings render CJC-1295 (No DAC) a primary standard in tissue regeneration and endocrine research.

In contrast, preclinical literature surrounding SLU-PP-332 focuses on cellular metabolic reprogramming. Experimental mouse models subjected to SLU-PP-332 treatment exhibit enhanced mitochondrial volume density, elevated maximum oxygen consumption (VO2 max), and accelerated lipid substrate preference during basal activity. Crucially, these physiological shifts occur independently of endocrine secretagogues or growth factor elevation, establishing SLU-PP-332 as a distinct tool for studying metabolic disease, mitochondrial dysfunction, and exercise biology.

Comparative Analysis with Adjacent Research Peptides

When designing peptide protocols targeting growth factor or metabolic pathways, researchers often evaluate CJC-1295 (No DAC) alongside other secretagogues. For instance, Sermorelin offers identical GHRH receptor selectivity with a shorter biological half-life (~12 minutes), whereas co-administration with ghrelin mimetics such as Ipamorelin produces synergistic GH releases via dual-receptor pathway activation. Conversely, researchers interested in direct mitochondrial gene expression and metabolic regulation often compare SLU-PP-332 with mitochondrial-derived peptides like MOTS-c. Laboratories can explore the complete catalog of purified research compounds by reviewing the PX1 catalog.

Protocol Selection: Matching Compound Characteristics to Study Design

Selecting between CJC-1295 (No DAC) and SLU-PP-332 depends entirely on the primary research hypothesis and cellular endpoints being investigated. If the experimental objective involves investigating protein synthesis, wound closure rate, bone mineral density, or pituitary response dynamics, CJC-1295 (No DAC) provides the necessary GHRH-R agonism to drive IGF-1 cascades.

If the study aims to measure basal metabolic rate, mitochondrial gene expression (e.g., UCP3, COX4), respiratory exchange ratio (RER), or endurance capacity independent of endocrine manipulation, SLU-PP-332 is the appropriate agent. For high-throughput screening or multi-center trial designs, researchers can consult our PX1 research library or set up wholesale lab accounts to ensure uniform lot procurement for longitudinal studies.

Laboratory Handling, Quality Standards, and Reconstitution

Rigorous research requires strict adherence to compound purity and handling protocols. CJC-1295 (No DAC) is supplied as a lyophilized, highly purified peptide powder. It should be stored at -20°C prior to reconstitution. Reconstitution should be performed using sterile or bacteriostatic water to achieve the desired molar concentration, utilizing our verified reconstitution calculator for precise dilution calculations.

SLU-PP-332, being a hydrophobic small-molecule compound, requires solubilization in organic solvents such as DMSO or ethanol before dilution into aqueous assay buffers. Every batch supplied by PX1 Research undergoes rigorous quality testing, including HPLC/MS mass verification, third-party laboratory verification published on every lot-specific COA, and strict endotoxin screening (<0.01 EU/µg) to guarantee reliable experimental outcomes.